

ASX RELEASE

23 JULY 2025

AMPLIA ANNOUNCES A\$25 MILLION PLACEMENT AND LAUNCHES A\$2.5 MILLION SPP

HIGHLIGHTS

- Capital raise of \$27.5 million (the **Capital Raise**) to support the ACCENT and AMPLICITY trials and support kRAS and ovarian cancer trials of the Company's lead drug, narmafotinib (AMP945).
- The Capital Raise comprises:
 - an institutional placement to raise A\$25 million (**Placement**); and
 - a Share Purchase Plan seeking to raise an additional A\$2.5 million (**SPP**).
- New Shares issued under the Placement are priced at \$0.23 each (**Placement Offer Price**).
- The Placement was strongly supported by existing and new institutional and sophisticated investors in Australia and offshore
- Firm commitments received from institutional investors for A\$2.5 million worth of shortfall shares under the SPP (in the event of a shortfall).
- Top-line data from the ACCENT trial is expected in late July/early August 2025
- Funds from the Capital Raise will enable the company to accelerate towards commencement of a potential pivotal phase 2b/3 trial in 2H 2026
- Following the Capital Raise the company will be funded into 2027.

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (**Amplia** or the **Company**), is pleased to announce that it has undertaken a successful A\$25.0 million institutional placement (**Placement**) of new, fully paid ordinary shares in the Company (**New Shares**) at a price of \$0.23 per New Share (**Placement Offer Price**).

The Placement will be followed by a share purchase plan (**SPP**) seeking to raise \$2.5 million (with the ability to accept over-subscriptions of up to an additional \$7.5 million) at the SPP offer price. Amplia has received firm commitments for \$2.5 million worth of shortfall shares under the SPP (in the event of a shortfall).

Commenting on the successful Capital Raise, Amplia Managing Director Dr Chris Burns commented: "We are extremely grateful for the support in this raise from our existing institutional and sophisticated investors, as well as from the new investors. The funds from the raise will support our ongoing clinical studies, along with planning for follow-on trials, to build on the exciting data already obtained for narmafotinib in the ACCENT study in pancreatic cancer."

Placement

The Placement comprises the following components:

- a placement utilising Amplia's existing placement capacity to raise approximately \$22.3 million (**Unconditional Placement**) via the issue of:
 - 57,937,087 New Shares under the Company's Listing Rule 7.1 capacity; and
 - 38,867,267 New Shares under the Company's Listing Rule 7.1A capacity;
- a placement to raise \$2.5 million to two large existing institutional shareholders via the issue of approximately 10.87 million New Shares, subject to shareholder approval for the purposes of Listing Rule 7.1 (**Conditional Placement**); and
- a placement to Amplia's directors to raise \$235,000 via the issue of approximately 1.02 million New Shares, subject to shareholder approval for the purposes of Listing Rule 10.11 (**Director Placement**).

The Placement Offer Price of \$0.23 per New Share represents a:

- discount of 19.3% to the closing price of Amplia shares on Friday, 18 July 2025 (of \$0.285);
- discount of 22.8% to the 5 trading day VWAP for the period ending Friday, 18 July 2025 (of \$0.298); and
- premium of 0.6% to the 30 trading day VWAP for the period ending Friday, 18 July 2025 (of \$0.229).

Settlement of the New Shares to be issued under the Unconditional Placement is expected to take place on Monday, 28 July 2025, with allotment and commencement of trading expected to occur on Tuesday, 29 July 2025.

Approval will be sought for the Conditional Placement and Director Placement at Amplia's Annual General Meeting to be held on Wednesday, 27 August 2025 (**AGM**). Assuming shareholder approval is obtained, settlement of the New Shares to be issued under the Conditional Placement and Director Placement is expected to take place on Friday, 29 August 2025 with allotment and commencement of trading expected to occur on Monday, 1 September 2025.

The Placement was strongly supported by new and existing domestic and international investors.

Share Purchase Plan

In conjunction with the Placement, the Company will offer existing shareholders the opportunity to participate in the SPP, which is seeking to raise a further A\$2.5 million.

Under the SPP, shareholders at 7:00pm (Sydney time) on the record date of Tuesday, 22 July with a registered address in Australia or New Zealand (**Eligible Shareholders**) will be offered the opportunity to apply for up to A\$100,000 of New Shares without any brokerage or transaction costs.

The SPP is being undertaken at the SPP Offer Price, which is the lower of:

- the Placement Offer Price (of \$0.23); and
- the price representing a discount of 5.0% to the VWAP of Amplia shares over the last 5 trading days of the SPP offer period, rounded (up or down) to the nearest half-cent.

The SPP is conditional on Amplia shareholder approval for the purposes of Listing Rule 7.1. Approval will be sought for the SPP at the AGM.

The SPP will be undertaken pursuant to a transaction-specific prospectus that is expected to be lodged with ASIC and ASX and made available to Eligible Shareholders on Friday, 1 August 2025 (**SPP Offer Booklet**).

The SPP is seeking to raise A\$2.5 million. Applications in excess of this amount may be scaled back in accordance with the scale back policy set out in the SPP Offer Booklet. In the event of a scale-back, any excess money will be refunded (without interest). Amplia has received firm commitments for \$2.5 million worth of shortfall shares under the SPP (in the event of a shortfall).

Amplia retains the discretion to accept over-subscriptions of up to an additional \$7.5 million of New Shares under the SPP.

The key dates for the SPP are set out in the timetable below.

Sources and Uses of Funds

Amplia intends to use its existing cash reserves, expected future R&D grants and the proceeds of the Capital Raise in accordance with the Use of Funds table below.

Sources of Funds	AUD (\$m)
Cash Balance (at 30 June 25) ¹	\$7.0
Expected FY25 and FY26 R&D Tax Refunds ²	\$8.2
Capital Raise	\$27.5
Total	\$42.7

¹ Unaudited – based on 31 March 2025 Appendix 4C and management accounts

² FY25 R&D tax refund expected August 2025 and FY26 R&D tax refund expected August 2026

Uses of Funds	AUD (\$m)
ACCENT trial <ul style="list-style-type: none"> Completion of Phase 2a Foundational work for Phase 2b/3 trial 	\$6.0
Amplicity trial <ul style="list-style-type: none"> Dose escalation 2 Dose comparison 	\$19.0
KRAS and/or Ovarian trial	\$5.0
CMC (manufacturing)	\$6.0
Operations, preclinical, working capital and offer costs	\$6.7
Total	\$42.7

Key Dates

The Capital Raise will be conducted according to the following indicative timetable:

Event	Date
Record Date for SPP (7.00pm, Melbourne time)	Tuesday, 22 July 2025
Announcement of Placement and SPP and Shares recommence trading on ASX	Wednesday, 23 July 2025
Settlement of the Unconditional Placement	Monday, 28 July 2025
Allotment of New Shares issued under the Unconditional Placement	Tuesday, 29 July 2025
SPP Offer Booklet made available to Eligible Shareholders Opening Date of SPP	Friday, 1 August 2025
Closing Date of SPP	Friday, 22 August 2025
Announcement of results of SPP	Tuesday, 26 August 2025
AGM	Wednesday, 27 August 2025
Settlement of Conditional Placement & Director Placement Issue of New Shares under the SPP	Friday, 29 August 2025
Allotment of New Shares issued under the Conditional Placement and Director Placement Normal ASX trading for New Shares issued under the SPP commences	Monday, 1 September 2025

* Please note the dates set out above are indicative only and are subject to change. All dates and times are references to Melbourne, Australia time.

Amplia reserves the right, subject to the *Corporations Act 2001* (Cth) and the ASX Listing Rules, to amend this indicative timetable. In particular, Amplia reserves the right to extend the closing date for the SPP, accept late applications under the SPP (either generally or in particular cases) and to withdraw the Placement or SPP without prior notice. Any extension of the closing date for the SPP will have a consequential effect on the date for the issue of New Shares.

Other Information

Further information about the Placement, SPP and the Company (including a description of some of the key risks involved in an investment in New Shares) can be found in the presentation lodged with ASX on 22 July 2025, which is available on the ASX's website (www.asx.com.au) and the Company's website (www.ampliatx.com).

Bell Potter Securities Limited acted as the sole Lead Manager to the Placement.

Evolution Capital Pty Ltd acted as Co-Manager to the Placement.

Becketts Lawyers acted as Australian legal adviser to Amplia.

The Company's shares will recommence trading on the ASX today (23 July 2025).

This ASX announcement was approved and authorised for release by the Managing Director of Amplia Therapeutics Limited.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx), and [LinkedIn](https://www.linkedin.com/company/ampliatx).

IMPORTANT INFORMATION

This announcement has been prepared for publication in Australia and may not be released to U.S. wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the U.S. Securities Act and applicable U.S. state securities laws.